Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213247 | 0.99 | KMT2A (0.43) | KMT2AUSP2HSD17B10TSHRMEN1 | |
| SCHEMBL14213239 | 0.92 | KMT2A (0.45) | KMT2AUSP2HSD17B10TSHRMEN1 | |
| SCHEMBL13992490 | 0.91 | KMT2A (0.46) | KMT2AUSP2HSD17B10TSHRMEN1 | |
| SCHEMBL16501695 | 0.89 | KMT2A (0.40) | KMT2AUSP2HSD17B10TSHRMEN1 | |
| SCHEMBL10046739 | 0.87 | LGALS1 (0.55) | KMT2AUSP2HSD17B10TSHRLGALS1 | |
| SCHEMBL14213241 | 0.86 | LGALS1 (0.54) | KMT2AUSP2HSD17B10TSHRLGALS1 | |
| SCHEMBL10046775 | 0.82 | KMT2A (0.51) | KMT2ATSHRMEN1LGALS1THRB | |
| SCHEMBL13992489 | 0.78 | LGALS1 (0.55) | KMT2ATSHRMEN1LGALS1THRB | |
| SCHEMBL14213234 | 0.73 | LMNA (0.36) | KMT2ATSHRALDH1A1LMNAHTT | |
| SCHEMBL13992476 | 0.72 | LGALS1 (0.63) | KMT2ATSHRMEN1LGALS1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207228-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-06-26 | — | — | US | disclosed |
| US-20080300164-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300164-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | KMT2A 4742/4885USP2 4076/4885HSD17B10 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.